|
Tender description :
|
Tenders are invited for multiple sourcing framework contracts to speed up the development of and access to innovative medical countermeasures
this call for tenders aims to speed up the development of next generation influenza vaccines that could be produced in rapidly scalable manufacturing platforms (e.g. nucleic acid approaches and/or production in scalable eukaryotic or bacterial cell culture, in plants or via in vitro transcription), could support products utilising novel administration routes (e.g. nasal, oral or through microneedle patches), confer mucosal immunity, target potentially pandemic influenza a viruses or could be rapidly adapted to pandemic influenza a viruses, which are protective across influenza subtypes or across alpha-influenza viruses, and/or possess intrinsic immunogenicity without the addition of adjuvants. the call will be implemented via a competitive development in phases as foreseen under pre-commercial procurement.
Estimated value excluding VAT:225 000 000,00EUR
|
